NASDAQ:SERA Sera Prognostics (SERA) Stock Price, News & Analysis $2.91 -0.02 (-0.68%) Closing price 04:00 PM EasternExtended Trading$3.06 +0.15 (+5.15%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Sera Prognostics Stock (NASDAQ:SERA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Sera Prognostics alerts:Sign Up Key Stats Today's Range$2.90▼$3.0750-Day Range$2.93▼$4.3252-Week Range$2.88▼$11.05Volume81,928 shsAverage Volume130,830 shsMarket Capitalization$109.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company OverviewSera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.Read More… Sera Prognostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreSERA MarketRank™: Sera Prognostics scored higher than 21% of companies evaluated by MarketBeat, and ranked 869th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Sera Prognostics.Read more about Sera Prognostics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Sera Prognostics are expected to decrease in the coming year, from ($0.96) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sera Prognostics is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sera Prognostics is -2.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSera Prognostics has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sera Prognostics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.36% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 18.18%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSera Prognostics does not currently pay a dividend.Dividend GrowthSera Prognostics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.36% of the float of Sera Prognostics has been sold short.Short Interest Ratio / Days to CoverSera Prognostics has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Sera Prognostics has recently decreased by 18.18%, indicating that investor sentiment is improving significantly. News and Social Media2.5 / 5News SentimentN/A News SentimentSera Prognostics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sera Prognostics this week, compared to 2 articles on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Sera Prognostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,288.00 in company stock.Percentage Held by Insiders15.80% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.64% of the stock of Sera Prognostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sera Prognostics' insider trading history. Receive SERA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter. Email Address SERA Stock News HeadlinesSera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025April 24, 2025 | prnewswire.comSera Prognostics: Initiating With Hold, Potential Of PreTRM Test, But Uncertain Commercial TimelineApril 15, 2025 | seekingalpha.comREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).May 2, 2025 | Weiss Ratings (Ad)Sera Prognostics Earnings Call: Balancing Success and ChallengesMarch 21, 2025 | tipranks.comSera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2024 Financial ResultsMarch 21, 2025 | finanznachrichten.deEarnings call transcript: Sera Prognostics Q4 2024 sees revenue drop, stock risesMarch 21, 2025 | uk.investing.comTD Cowen Sticks to Its Buy Rating for Sera Prognostics (SERA)March 21, 2025 | markets.businessinsider.comSera Prognostics Full Year 2024 Earnings: Misses ExpectationsMarch 21, 2025 | finance.yahoo.comSee More Headlines SERA Stock Analysis - Frequently Asked Questions How have SERA shares performed this year? Sera Prognostics' stock was trading at $8.14 on January 1st, 2025. Since then, SERA stock has decreased by 64.3% and is now trading at $2.91. View the best growth stocks for 2025 here. How were Sera Prognostics' earnings last quarter? Sera Prognostics, Inc. (NASDAQ:SERA) announced its quarterly earnings data on Wednesday, March, 19th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.02. The business earned $0.02 million during the quarter, compared to analyst estimates of $0.01 million. Read the conference call transcript. When did Sera Prognostics IPO? Sera Prognostics (SERA) raised $75 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 4,687,500 shares at a price of $15.00-$17.00 per share. Who are Sera Prognostics' major shareholders? Top institutional shareholders of Sera Prognostics include Bank of New York Mellon Corp (0.36%), Wealth Enhancement Advisory Services LLC (0.26%), Sanders Morris Harris LLC (0.25%) and Rhumbline Advisers (0.11%). Insiders that own company stock include Zhenya Lindgardt, Austin Aerts, Paul Kearney, John J Boniface, Robert Gardner Harrison, Mansoor Raza Mirza and Joshua Phillips. View institutional ownership trends. How do I buy shares of Sera Prognostics? Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sera Prognostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sera Prognostics investors own include Meta Platforms (META), JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Advanced Micro Devices (AMD) and Home Depot (HD). Company Calendar Last Earnings3/19/2025Today5/02/2025Next Earnings (Estimated)5/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:SERA CIK1534969 Webwww.seraprognostics.com Phone801-990-0520FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,240,000.00 Net MarginsN/A Pretax Margin-34,302.13% Return on Equity-51.73% Return on Assets-36.94% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio2.11 Sales & Book Value Annual Sales$77,000.00 Price / Sales1,457.65 Cash FlowN/A Price / Cash FlowN/A Book Value$2.21 per share Price / Book1.35Miscellaneous Outstanding Shares37,664,000Free Float28,436,000Market Cap$112.24 million OptionableOptionable Beta0.96 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:SERA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sera Prognostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sera Prognostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.